ValuEngine Upgrades Recro Pharma (REPH) to Hold

Share on StockTwits

Recro Pharma (NASDAQ:REPH) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

A number of other research firms have also recently weighed in on REPH. Roth Capital set a $9.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Saturday, May 26th. Zacks Investment Research raised shares of Recro Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, May 31st. Oppenheimer set a $18.00 price objective on shares of Recro Pharma and gave the company a “buy” rating in a research report on Wednesday, August 8th. Janney Montgomery Scott decreased their price objective on shares of Recro Pharma from $21.00 to $11.00 and set a “fair value” rating for the company in a research report on Thursday, May 24th. Finally, BidaskClub raised shares of Recro Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, May 24th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $12.63.

NASDAQ:REPH opened at $9.02 on Tuesday. The company has a debt-to-equity ratio of 2.22, a current ratio of 1.59 and a quick ratio of 1.42. The stock has a market capitalization of $132.18 million, a price-to-earnings ratio of -4.53 and a beta of -0.82. Recro Pharma has a 1-year low of $4.78 and a 1-year high of $13.05.

Recro Pharma (NASDAQ:REPH) last posted its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.72. The company had revenue of $21.74 million during the quarter, compared to analysts’ expectations of $16.81 million. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. sell-side analysts expect that Recro Pharma will post -2.5 earnings per share for the current fiscal year.

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Recro Pharma by 211.8% during the first quarter. JPMorgan Chase & Co. now owns 98,751 shares of the specialty pharmaceutical company’s stock worth $1,087,000 after purchasing an additional 67,078 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Recro Pharma during the first quarter worth about $139,000. Sphera Funds Management LTD. bought a new position in shares of Recro Pharma during the first quarter worth about $4,010,000. The Manufacturers Life Insurance Company lifted its position in shares of Recro Pharma by 6,480.5% during the first quarter. The Manufacturers Life Insurance Company now owns 235,712 shares of the specialty pharmaceutical company’s stock worth $2,595,000 after purchasing an additional 232,130 shares during the last quarter. Finally, Jump Trading LLC bought a new position in shares of Recro Pharma during the first quarter worth about $124,000. 55.86% of the stock is currently owned by institutional investors and hedge funds.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Article: What is a Leveraged Buyout (LBO)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply